833 Shares in Axon Enterprise, Inc (NASDAQ:AXON) Acquired by Quotient Wealth Partners LLC

Quotient Wealth Partners LLC purchased a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 833 shares of the biotechnology company's stock, valued at approximately $438,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AXON. Brighton Jones LLC purchased a new position in Axon Enterprise during the 4th quarter worth approximately $480,000. Proficio Capital Partners LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at $78,414,000. Dorsey & Whitney Trust CO LLC bought a new stake in shares of Axon Enterprise during the 4th quarter worth about $244,000. AlphaQuest LLC lifted its stake in shares of Axon Enterprise by 255.5% in the fourth quarter. AlphaQuest LLC now owns 871 shares of the biotechnology company's stock worth $518,000 after buying an additional 626 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in Axon Enterprise by 84.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 18,268 shares of the biotechnology company's stock valued at $10,857,000 after acquiring an additional 8,341 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Stock Down 0.5%

AXON traded down $3.37 during trading on Friday, hitting $729.62. The company had a trading volume of 1,120,957 shares, compared to its average volume of 545,551. The firm's 50-day moving average price is $752.67 and its 200 day moving average price is $640.95. The company has a market capitalization of $56.80 billion, a PE ratio of 176.24, a PEG ratio of 84.37 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. Axon Enterprise, Inc has a one year low of $279.02 and a one year high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company's revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.15 EPS. As a group, equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Activity

In related news, CRO Cameron Brooks sold 3,000 shares of Axon Enterprise stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the completion of the transaction, the executive owned 19,447 shares in the company, valued at approximately $14,405,559.72. This trade represents a 13.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Jennifer H. Mak sold 75 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total transaction of $57,885.75. Following the completion of the transaction, the chief accounting officer directly owned 15,240 shares in the company, valued at $11,762,384.40. The trade was a 0.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of research reports. The Goldman Sachs Group boosted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Wolfe Research began coverage on shares of Axon Enterprise in a report on Monday. They issued an "outperform" rating on the stock. Barclays raised their price target on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Bank of America increased their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Finally, Needham & Company LLC lifted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise presently has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.